Genetic modifiers of multiple sclerosis progression, severity and onset

19Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The genetic contribution to clinical outcomes for multiple sclerosis (MS) has yet to be defined. We performed exome sequencing analysis in 100 MS patients presenting opposite extremes of clinical phenotype (discovery cohort), and genotyped variants of interest in 2016 MS patients (replication cohort). Linear and logistic regression analyses were used to identify significant associations with disease course, severity and onset. Our analysis of the discovery cohort nominated 38 variants in 21 genes. Replication analysis identified PSMG4 p.W99R and NLRP5 p.M459I to be associated with disease severity (p = 0.002 and 0.008). CACNA1H p.R1871Q was found associated with patients presenting relapsing remitting MS at clinical onset (p = 0.028) whereas NLRP5 p.M459I and EIF2AK1 p.K558R were associated with primary progressive disease (p = 0.031 and 0.023). In addition, PSMG4 p.W99R and NLRP5 p.R761L were found to correlate with an earlier age at MS clinical onset, and MC1R p.R160W with delayed onset of clinical symptoms (p = 0.010–0.041).

Cite

CITATION STYLE

APA

Sadovnick, A. D., Traboulsee, A. L., Zhao, Y., Bernales, C. Q., Encarnacion, M., Ross, J. P., … Vilariño-Güell, C. (2017). Genetic modifiers of multiple sclerosis progression, severity and onset. Clinical Immunology, 180, 100–105. https://doi.org/10.1016/j.clim.2017.05.009

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free